Neurochemistry and the non-motor aspects of PD
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Parkinson disease (PD) is a systemic disease with variegated non-motor deficits and neurological symptoms, including impaired olfaction, autonomic failure, cognitive impairment and psychiatric symptoms, in addition to the classical motor symptoms. Many non-motor symptoms appear before or in parallel with motor deficits and then worsen with disease progression. Although there is a relationship, albeit not causal, between motor symptoms and the presence of Lewy bodies (LBs) and neurites filled with abnormal α-synuclein, other neurological alterations are independent of the amount of α-synuclein inclusions in neurons and neurites, thereby indicating that different mechanisms probably converge in the degenerative process. This may apply to complex alterations interfering with olfactory and autonomic nervous systemfunctions, emotions, sleep regulation, and behavioral, cognitive and mental performance. Involvement of the cerebral cortex leading to impaired behavior and cognition is related to several convergent altered factors including: a. dopaminergic, noradrenergic, serotoninergic and cholinergic cortical innervation; b. synapses; c. cortical metabolism; d. mitochondrial function and energy production; e. oxidative damage; f. transcription; g. protein expression; h. lipid composition; and i. ubiquitin–proteasome system and autophagy, among others. This complex situation indicates that multiple subcellular failure in selected cell populations is difficult to reconcilewith a reductionistic scenario of a single causative cascade of events leading to non-motor symptoms in PD. Furthermore, these alterationsmay appear at early stages of the disease and may precede the appearance of substantial irreversible cell loss by years. These observations have important implications in the design of therapeutic approaches geared to prevention and treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 3×
“α-synuclein pathology affecting neurons and neurites occurs in the olfactory bulb and related olfactory nuclei at very early stages of PDrelated pathology (Bloch et al., 2006; Braak et al., 2003, 2004; Daniel and Hawkes, 1992; Del Tredici et al., 2002; Hubbard et al., 2007; Pearce et al., 1995).”
BackgroundMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 1×
“…mitochondrial integrity were shown to be causative of familial PD, including DJ1, PINK1, LRRK2, HtrA2 and parkin (AbouSleiman et al., 2006; Clark et al., 2006; Dodson and Guo, 2007; Park et al., 2006; Poole et al., 2008; Sack, 2009; Silvestri et al., 2005; Smith et al., 2005; Ved et al.,…”
BackgroundMitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 2×
“Later on, several genes encoding proteins relevant to maintaining mitochondrial integrity were shown to be causative of familial PD, including DJ1, PINK1, LRRK2, HtrA2 and parkin (AbouSleiman et al., 2006; Clark et al., 2006; Dodson and Guo, 2007; Park et al., 2006; Poole et al., 2008; Sack, 2009; Silvestri et al., 20…”
BackgroundBraak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354 · cited 8×
“Research on protein expression in the neocortex in LBDs is more limited (Caudle et al., 2010; Pan et al., 2007; Shi et al., 2008).”
BackgroundInfluentialMitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972 · cited 2×
“…nuclei of the brain stem, and dorsalmotor nucleus of the vagus, aswell as the basal nucleus of Meynert, the amygdala and the CA2 area of the hippocampus (Braak and del Tredici, 2008; Braak et al., 1999; Dickson, 2001; Dickson et al., 2009a,b; Forno, 1996; Goedert 2001; Jellinger and Mizuno, 2003).”
BackgroundSaijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 957 · cited 2×
“CoREST pathway (Saijo et al., 2009), by removing toxic molecules from the extracellular space and through the release of throfic factors”
BackgroundArizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
The PINK1/Parkin pathway regulates mitochondrial morphology
Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., & Pallanck, L. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709336105 · Cited by 885 · cited 2×
“…of familial PD, including DJ1, PINK1, LRRK2, HtrA2 and parkin (AbouSleiman et al., 2006; Clark et al., 2006; Dodson and Guo, 2007; Park et al., 2006; Poole et al., 2008; Sack, 2009; Silvestri et al., 2005; Smith et al., 2005; Ved et al., 2005; Winklhofer and Haass, 2010; Yang et al., 2005).”
BackgroundMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 2×
“In addition, white matter hyperintensities are more frequent in PD cases with altered cognition than in cases with preserved cognitive functions (Lee et al., 2010a,b).”
BackgroundExpanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773 · cited 3×
“However, depressive symptoms in PD correlate with increased serotonin transporter (Politis et al., 2010) and with a loss of dopamine and noradrenaline innervation (Delaveau et al., 2009; Remy et al., 2005) in amygdala and other limbic structures.”
BackgroundThomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 1×
“Glial cell pathology in neocortex Glial reactions in toxic-induced and transgenic models of PD, and in the substantia nigra in PD have a role in the pathogenesis of dopaminergic damage (Chung et al., 2010; Halliday and Stevens, 2011; McGeer and McGeer, 2008; Yokoyama et al., 2011).”
BackgroundMitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Repression of α-synuclein expression and toxicity by microRNA-7
Junn, E., Lee, K.-W., Jeong, B. S., Chan, T. W., Im, J.-Y., & Mouradian, M. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906277106 · Cited by 655 · cited 1×
“…also appears to be regulated post-transcriptionally by microRNAs mir-7 and mir-153, which bind specifically to the 3′- untranslated region of α-synuclein and down-regulate its mRNA and protein levels, thus decreasing endogenous expression of α-synuclein (Doxakis, 2010; Junn et al., 2009).”
BackgroundProteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653 · cited 1×
“…a few examples of differences of oppinion related to human post-mortem brain of sporadic PD, abnormal function of the UPS has been been reported in some studies (McNaught and Jenner, 2001; McNaught et al., 2002, 2003), but this observation has not been corroborated in others (Tofaris et al., 2003).”
Resultα-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573 · cited 1×
“…a few examples of differences of oppinion related to human post-mortem brain of sporadic PD, abnormal function of the UPS has been been reported in some studies (McNaught and Jenner, 2001; McNaught et al., 2002, 2003), but this observation has not been corroborated in others (Tofaris et al., 2003).”
ResultChoi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568 · cited 2×
“In addition, DJ-1 in astrocytes modulates the innate immunity signaling (Cornejo Castro et al., 2010) and confers neuroprotection to neighboring neurons (Mullett and Hinkle, 2011).”
BackgroundHypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566 · cited 2×
“Hypocretin (orexin) cell loss following an anterior-to-posterior gradient has been found in the hypothalamus of PD cases with disease progression, and this finding has been proposed as a morphological and biochemical substrate of sleep alterations (Fronczek et al., 2007; Thannickal et al., 2007).”
BackgroundLippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses
Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E., & Ikuta, F. (1988) · Acta Neuropathologica · doi:10.1007/bf00687767 · Cited by 528 · cited 1×
“…and abnormal solubility, and is prone to the formation of aggregates and insoluble fibrils (Anderson et al., 2006; Baba et al., 1998; Duda et al., 2000; Fujiwara et al., 2002; Giasson et al., 2002; Hashimoto and Masliah, 1999; Iwatsubo, 2003; Spillantini et al., 1997;Wakabayashi et al., 1998).”
BackgroundHypocretin (orexin) loss in Parkinson's disease
Fronczek, R., Overeem, S., Lee, S. Y. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., Lammers, G. J., & Swaab, D. F. (2007) · Brain · doi:10.1093/brain/awm090 · Cited by 463 · cited 2×
“Hypocretin (orexin) cell loss following an anterior-to-posterior gradient has been found in the hypothalamus of PD cases with disease progression, and this finding has been proposed as a morphological and biochemical substrate of sleep alterations (Fronczek et al., 2007; Thannickal et al., 2007).”
BackgroundBraak, H., Sastre, M., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0244-3 · Cited by 462 · cited 1×
“Little is known about glial reactions in the neocortex in PD. αsynuclein in astrocytes has been reported in the amygdala, thalamus, septum, striatum, claustrum and cerebral cortex in PD, probably as a result of α-synuclein leakage from projection neurons to these areas (Braak et al., 2007).”
BackgroundAlzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of α-Synucleinopathy
Uchikado, H., Lin, W.-L., DeLucia, M. W., & Dickson, D. W. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000225908.90052.07 · Cited by 359
Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease
Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., & Ferrer, I. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000179050.54522.5a · Cited by 261 · cited 3×
“…of cortical membranes: lipid rafts Abnormal lipid composition occurs in the frontal cortex at very early stages of PD-related pathology with significantly increased expression levels of the highly peroxidizable docosahexanoic acid (DHA), and increased peroxidability index (Dalfó et al., 2005).”
BackgroundSelf-citationEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 1×
“Of note, this disease is directly caused by the accumulation of saturated very long chain fatty acids and the ensuing oxidative damage this excess generates in the cels (Ferrer et al., 2010; Fourcade et al., 2008; LópezErauskin et al., 2011).”
BackgroundSelf-citationLewy Body Pathology in Normal Elderly Subjects
Markesbery, W. R., Jicha, G. A., Liu, H., & Schmitt, F. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ac10a7 · Cited by 210
Hague, K., Lento, P., Morgello, S., Caro, S., & Kaufmann, H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050693 · Cited by 209 · cited 2×
“…(intermediodorsal nucleus of the thoracic cord and sympathetic ganglia) and parasympathetic system (dorsal vagal and sacral parasympathetic nuclei, and peripheral parasympathetic ganglia), as well as the enteric plexus (Hague et al., 1997; Micieli et al., 2003; Wakabayashi and Takahashi, 1997).”
BackgroundAuditory hallucinations in Parkinson's disease
Inzelberg, R., Kipervasser, S., & Korczyn, A. D. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.4.533 · Cited by 179 · cited 1×
“Visual and auditory hallucinations, agitated confusion, vivid dreaming, delirium and delusions are common in PD (Doe De Maindreville et al., 2005; Inzelberg et al., 1998; Papapetropoulos and Mash, 2005; Sanchez-Ramos et al., 1966; Wolters, 2001).”
BackgroundAutonomic dysfunction in Parkinson's disease
Micieli, G., Tosi, P., Marcheselli, S., & Cavallini, A. (2003) · Neurological Sciences · doi:10.1007/s100720300035 · Cited by 157
General aspects and neuropathology of X-linked adrenoleukodystrophy
Ferrer, I., Aubourg, P., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00390.x · Cited by 139 · cited 1×
“Of note, this disease is directly caused by the accumulation of saturated very long chain fatty acids and the ensuing oxidative damage this excess generates in the cels (Ferrer et al., 2010; Fourcade et al., 2008; LópezErauskin et al., 2011).”
BackgroundSelf-citationTanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0676-z · Cited by 102
Parkinsons Disease and other α-Synucleinopathies
Goedert, M. (2001) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2001.047 · Cited by 96 · cited 1×
“…nuclei of the brain stem, and dorsalmotor nucleus of the vagus, aswell as the basal nucleus of Meynert, the amygdala and the CA2 area of the hippocampus (Braak and del Tredici, 2008; Braak et al., 1999; Dickson, 2001; Dickson et al., 2009a,b; Forno, 1996; Goedert 2001; Jellinger and Mizuno, 2003).”
BackgroundHashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78 · cited 2×
“Altered metabolic events at the synapses may impair synaptic function and aberrant synaptic plasticicity in PD (Hashimoto and Masliah, 2003).”
Background
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Biomarkers of Parkinson’s disease: Present and future
Miller, D. B., & O’Callaghan, J. P. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 358
Olfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Crespo, I., Perumal, T. M., Jurkowski, W., Antony, P. M. A., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8489-4 · Cited by 273
Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195
Self-citation
Metadata
- Authors
- Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 46
- Issue
- 3
- Pages
- 508-526
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2074825064
- Cited by
- 87
- References
- 41
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.